Direct In Vivo Xenograft Tumor Model for Predicting Chemotherapeutic Drug Response in Cancer Patients
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
It is estimated that the development of a new anticancer agent costs US$800 million to 1 billion and takes more than a decade between conception and approval.1 However, 90% of novel antineoplastic drugs fail in the clinic despite evidence of antitumor efficacy in classical preclinical models.2 This raises serious concerns as to whether such models are predictive of drug efficacy in humans, particularly in the current era of new targeted therapies, and supports the development of alternative approaches. Clinical Pharmacology & Therapeutics (2009); 85, 2, 217–221 doi:10.1038/clpt.2008.200
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265
Role of tissue stroma in cancer cell invasion
De Wever, O., & Mareel, M. (2003) · The Journal of Pathology · doi:10.1002/path.1398 · Cited by 1,042
Cited by
Hidalgo, M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0901557 · Cited by 2,570
Self-citationGuidelines for the welfare and use of animals in cancer research
An ad hoc committee of the National Cancer Research Institute, Workman, P., Aboagye, E. O., Balkwill, F., Balmain, A., Bruder, G., Chaplin, D. J., Double, J. A., Everitt, J., Farningham, D. A. H., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605642 · Cited by 1,442
Patient-derived tumour xenografts as models for oncology drug development
Tentler, J. J., Tan, A. C., Weekes, C. D., Jimeno, A., Leong, S., Pitts, T. M., Arcaroli, J. J., Messersmith, W. A., & Eckhardt, S. G. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.61 · Cited by 1,277
Patient-Derived Tumor Xenografts: Transforming Clinical Samples into Mouse Models
Siolas, D., & Hannon, G. J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1069 · Cited by 669
Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice
Kim, M. P., Evans, D. B., Wang, H., Abbruzzese, J. L., Fleming, J. B., & Gallick, G. E. (2009) · Nature Protocols · doi:10.1038/nprot.2009.171 · Cited by 380
Lin, D., Wyatt, A. W., Xue, H., Wang, Y., Dong, X., Haegert, A., Wu, R., Brahmbhatt, S., Mo, F., Jong, L., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2921-t · Cited by 364
Julien, S., Merino-Trigo, A., Lacroix, L., Pocard, M., Goéré, D., Mariani, P., Landron, S., Bigot, L., Nemati, F., Dartigues, P., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0372 · Cited by 360
Rajeshkumar, N. V., De Oliveira, E., Ottenhof, N., Watters, J., Brooks, D., Demuth, T., Shumway, S. D., Mizuarai, S., Hirai, H., Maitra, A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2580 · Cited by 274
Self-citationModeling of Patient-Derived Xenografts in Colorectal Cancer
(2017) · doi:10.1158/1535-7163.mct-16-0721 · Cited by 64
Pre-clinical Models of Metastasis in Pancreatic Cancer
Miquel, M., Zhang, S., & Pilarsky, C. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.748631 · Cited by 53
Dong, R., Qiang, W., Guo, H., Xu, X., Kim, J. J., Mazar, A., Kong, B., & Wei, J.-J. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0318-6 · Cited by 49
Perkhofer, L., Walter, K., Costa, I. G., Carrasco, M. C. R., Eiseler, T., Hafner, S., Genze, F., Zenke, M., Bergmann, W., Illing, A., et al. (2016) · Stem Cell Research · doi:10.1016/j.scr.2016.08.007 · Cited by 39
“Thereforewe extended our investigation to three patient xenograft-derived primary cell lines (Panc354, Panc185, Panc215) that were generated as described previously (Rubio-Viqueira and Hidalgo, 2009; Lonardo et al., 2011).”
Background
Metadata
- Authors
- Rubio-Viqueira, B., & Hidalgo, M.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2008-11-12
- Volume
- 85
- Issue
- 2
- Pages
- 217-221
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2039058362
- Cited by
- 134
- References
- 3
- FWCI
- 2.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.